Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Team Grant: E-Rare Joint Transnational Call

McGill University

$225,000.00

Designing a toolbox of paradigmatic treatments for a targeted molecular medicine approach to autosomal-recessive ataxias

FY 2020-21

Summary
Autosomal-recessive cerebellar ataxia (ARCA) is a heterogeneous group of rare neurodegenerative genetic diseases that share the common hallmark of progressive damage to parts of the nervous system that coordinate movement, such as the cerebellum. Despite its devastating consequences in daily life on mobility and communication and reduced life span, no disease-modifying treatment is available for these disabling disorders. TREAT-ARCA aims at designing and testing new complementary treatment strategies, including both repurposed and newly identified molecules, as well as gene therapies in two exemplary multisystemic flagship ARCAS: Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) and COQ8Aataxia (ARCA2). In addition, TREAT-ARCA aims at identifying and validating biomarkers that will enable to follow treatment. This will directly complement our consortium's prior clinical trial readiness work on these ARCAs (see PREPARE consortium; www.prepare-ataxia.com), thus now attaining all prerequisites required for directly facilitating clinical treatment trials in these two ARCAs
Program
Team Grant: E-Rare Joint Transnational Call
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
430840
Name
Brais Bernard
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
INSERM (Bordeaux, France); German Federal Ministry of Research, Technology and Space (Berlin); Fonds de recherche du Québec - Santé (FRQS); The French National Research Agency (France); Ministero della Salute (Italy)
Instname2
Genetics
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Designing a toolbox of paradigmatic treatments for a targeted molecular medicine approach to autosomal-recessive ataxias
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$225,000
Cihrequipment2
$0
Programname2
Team Grant: E-Rare Joint Transnational Call
Keyworddelim
Ataxia; Biomarker Discovery; Biomarker Validation; Drug Development; Drug Validation; Proteomics; Transcriptomics; Transgenic Mice Models
Abstract
Autosomal-recessive cerebellar ataxia (ARCA) is a heterogeneous group of rare neurodegenerative genetic diseases that share the common hallmark of progressive damage to parts of the nervous system that coordinate movement, such as the cerebellum. Despite its devastating consequences in daily life on mobility and communication and reduced life span, no disease-modifying treatment is available for these disabling disorders. TREAT-ARCA aims at designing and testing new complementary treatment strategies, including both repurposed and newly identified molecules, as well as gene therapies in two exemplary multisystemic flagship ARCAS: Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS) and COQ8Aataxia (ARCA2). In addition, TREAT-ARCA aims at identifying and validating biomarkers that will enable to follow treatment. This will directly complement our consortium's prior clinical trial readiness work on these ARCAs (see PREPARE consortium; www.prepare-ataxia.com), thus now attaining all prerequisites required for directly facilitating clinical treatment trials in these two ARCAs
Competitiondate
202006
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Brais, Bernard
Approvedterm
3 ans 0 mois
Cihrcontribution2
Institute of Genetics~ $225,000~ $0~
McGill University - $225,000 Grant (2020-21) | Canada Spends